Answers are grounded in this paper and cite their sources.
Preliminary evaluation reveals peptide effectiveness in tau degradation, suggesting further investigation is needed.
Tau reduction through targeted degradation has motivated several molecular strategies, including small-molecule degraders and peptide-based approaches. We designed a 47-amino-acid bifunctional peptide (GS-47) comprising a computationally selected tau-targeting segment, a glycine-serine linker, and the p62/SQSTM1-derived LC3-interacting region sequence DDDWTHLSS. The tau-targeting module was generated using RFdiffusion and ProteinMPNN against the tau filament structure PDB 8TTL and evaluated using predicted structural confidence metrics. GS-47 was tested in SH-SY5Y cells using a 24-hour endpoint Human MAPTau sandwich ELISA, with QC-01-175 as a PROTAC comparator and YA041 as an antibody reference. At the 1:10 ELISA dilution, GS-47 and QC-01-175 produced similar A450 values (0.227 and 0.231, respectively), both within the detectable standard range. Vehicle controls failed quality control, preventing normalization and formal quantitative comparison. We present this as a preliminary design-and-assay observation that motivates repeat experiments with normalization controls, orthogonal tau measurements, and mechanism-specific perturbations.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: